CytomX Therapeutics, Inc. - Common Stock (CTMX)
CUSIP: 23284F105
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 169,491,059
- Total 13F shares
- 137,411,371
- Share change
- +4,106,260
- Total reported value
- $438,342,190
- Put/Call ratio
- 17%
- Price per share
- $3.19
- Number of holders
- 102
- Value change
- +$24,527,196
- Number of buys
- 60
- Number of sells
- 37
Quarterly Holders Quick Answers
What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 23284F105:
Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.4%
|
15,561,500
|
$49,641,185 | +$8,195,110 | 30 Sep 2025 | |
| VR Adviser, LLC |
13F
|
Company |
8.2%
|
13,969,882
|
$31,711,632 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
6.5%
|
11,065,662
|
$25,119,053 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
5.9%
|
9,680,185
|
$22,458,029 | $0 | 14 Aug 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.5%
|
9,379,794
|
$21,292,133 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
5.5%
|
9,238,868
|
$20,972,230 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
5%
|
8,461,500
|
$19,207,605 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
2.5%
from 13D/G
|
8,084,623
|
$18,352,094 | — | 30 Jun 2025 | |
| Commodore Capital LP |
13F
|
Company |
4.5%
|
7,692,300
|
$17,461,521 | — | 30 Jun 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
3.5%
|
5,769,231
|
$17,250,001 | -$17,250,001 | 03 Jul 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
3.4%
|
5,769,230
|
$13,096,152 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3.4%
|
5,769,230
|
$13,096,152 | — | 30 Jun 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
2.3%
|
3,896,582
|
$8,845,241 | — | 30 Jun 2025 | |
| Longitude Capital Partners V, LLC |
13D/G
|
— |
7.3%
|
11,538,461
|
$8,192,307 | $0 | 13 May 2025 | |
| Prosight Management, LP |
13F
|
Company |
2.1%
|
3,517,113
|
$7,983,847 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.1%
|
3,484,226
|
$7,909,193 | — | 30 Jun 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2%
|
3,461,500
|
$7,857,605 | — | 30 Jun 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.8%
|
3,081,414
|
$6,994,810 | — | 30 Jun 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.7%
|
2,865,625
|
$6,504,969 | — | 30 Jun 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.6%
|
2,661,331
|
$6,041,221 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.4%
|
2,388,453
|
$5,421,788 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
2,353,122
|
$5,341,588 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
2,336,899
|
$5,304,761 | — | 30 Jun 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
1.3%
|
2,154,413
|
$4,890,518 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
1,862,200
|
$4,227,194 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
1,745,176
|
$3,963,288 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.92%
|
1,557,036
|
$3,533,000 | — | 30 Jun 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.77%
|
1,304,300
|
$2,960,761 | — | 30 Jun 2025 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.5%
|
844,643
|
$1,917,340 | — | 30 Jun 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.42%
|
720,020
|
$1,634,445 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.38%
|
639,040
|
$1,450,621 | — | 30 Jun 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.37%
|
630,809
|
$1,432,000 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.27%
|
450,107
|
$1,021,743 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
408,035
|
$926,239 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.2%
|
339,206
|
$769,998 | — | 30 Jun 2025 | |
| Formidable Asset Management, LLC |
13F
|
Company |
0.18%
|
312,850
|
$710,170 | — | 30 Jun 2025 | |
| Tidal Investments LLC |
13F
|
Company |
0.18%
|
312,850
|
$710,170 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
291,896
|
$662,604 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.17%
|
283,560
|
$643,681 | — | 30 Jun 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.15%
|
254,580
|
$577,897 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
252,659
|
$573,536 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.14%
|
243,547
|
$552,000 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.14%
|
233,339
|
$529,680 | — | 30 Jun 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.12%
|
201,224
|
$456,778 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.11%
|
183,166
|
$415,787 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.09%
|
157,681
|
$357,936 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
126,000
|
$286,020 | — | 30 Jun 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.07%
|
121,899
|
$276,711 | — | 30 Jun 2025 | |
| Seven Fleet Partners LP |
13D/G
|
— |
0.2%
|
377,161
|
$267,784 | $0 | 13 May 2025 | |
| Aspire Growth Partners LLC |
13F
|
Company |
0.06%
|
102,254
|
$232,117 | — | 30 Jun 2025 |
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock (CTMX) as of Q3 2025
As of 30 Sep 2025,
CytomX Therapeutics, Inc. - Common Stock (CTMX) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
137,411,371 shares.
The largest 10 holders included
VR ADVISER, LLC, FMR LLC, TANG CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, Commodore Capital LP, BAKER BROS. ADVISORS LP, Point72 Asset Management, L.P., and ADAR1 Capital Management, LLC.
This page lists
102
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
82
Q3 2025 holders
102
Holder diff
20
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.